CNS Pharmaceuticals Inc CNSP:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/03/24 EDT
0.2211quote price arrow up+0.0056 (+2.59%)
Volume
81,336
52 week range
0.19 - 2.98
Loading...
  • Open0.22
  • Day High0.2289
  • Day Low0.2102
  • Prev Close0.2155
  • 52 Week High2.98
  • 52 Week High Date06/02/23
  • 52 Week Low0.19
  • 52 Week Low Date04/17/24

Key Stats

  • Market Cap2.351M
  • Shares Out10.63M
  • 10 Day Average Volume0.09M
  • Dividend-
  • Dividend Yield-
  • Beta1.18
  • YTD % Change-82.59

KEY STATS

  • Open0.22
  • Day High0.2289
  • Day Low0.2102
  • Prev Close0.2155
  • 52 Week High2.98
  • 52 Week High Date06/02/23
  • 52 Week Low0.19
  • 52 Week Low Date04/17/24
  • Market Cap2.351M
  • Shares Out10.63M
  • 10 Day Average Volume0.09M
  • Dividend-
  • Dividend Yield-
  • Beta1.18
  • YTD % Change-82.59

RATIOS/PROFITABILITY

  • EPS (TTM)-5.76
  • P/E (TTM)-0.04
  • Fwd P/E (NTM)-0.09
  • EBITDA (TTM)-18.861M
  • ROE (TTM)-1,018.78%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-6.79%

EVENTS

  • Earnings Date05/15/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On CNS Pharmaceuticals Inc

 

Profile

MORE
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and CNS oncology indications, including...
Faith Charles J.D.
Independent Non-Executive Chairman of the Board
John Climaco Esq.
Chief Executive Officer, Director
Christopher Downs CPA
Chief Financial Officer
Address
2100 West Loop S Ste 900
Houston, TX
77027-3522
United States